Immunomedics

TRODELVY

Manufacturer:

Immunomedics

Trodelvy HCPCS:

J9317

HCPCS Code Descriptor:

Injection, sacituzumab govitecan-hziy, 2.5 mg

Category:

J Code

Trodelvy NDCs:

55135-0132-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Trodelvy:

TRODELVY is an Oncology drug manufactured by Immunomedics and administered via the Intravenous route of administration. The J Code: J9317 is aligned to the drug TRODELVY.

ACCESS PRICING AND MORE BY REGISTERING

J9317 Added Date:

January 1, 2021

J9317 Effective Date:

January 1, 2021

J9317 Termination Date:

HCPCS Active

Trodelvy billing and coding information can be found through Immunomedics at the link below:
Trodelvy patient assistance information can be found through Gilead at the URL: https://www.trodelvy.com/
TRODELVY prescribing information can be found at the link below:
Information regarding TRODELVY’s side effects can be found at MedlinePlus